BrightPath Biotherapeutics Co., Ltd
Looking for a EU partner for licensing agreement
| KEY ACTIVITIES | Drug and drug discovery |
| SECTOR: | Pharmaceutical |
| KEY WORDS: | Cancer cell, Immuno-modulatory antibody |
| TYPE OF ACTIVITIES | R&D cooperation |
Company Activity Description:
BrightPath Biotherapeutics is a Japan-based clinical-stage biopharmaceutical company focused on research and development of novel cancer immunotherapeutics. The company pipeline includes cancer peptide vaccine, rejuvenated T-cell therapy, and immuno-modulator antibodies.
BrightPath Biotherapeutics is also conducting research and development regarding cancer neoantigen.
Type of Partnership Sought:
| 1.License agreement |
Additional information:
BrightPath Biotherapeutics is aiming to license its latest researches.
# Out-license of GRN-1201 and GRN-1301
# In-license/collaboration of research or early-stage clinical programs and related technologies regarding;
- Cancer cell therapy
- Immuno-modulatory antibody
- Cancer neoantigen
| Products & Service | Stage | Outline |
| 1) GRN-1201 | Phase 2 in combination with immuno-checkpoint inhibitor (Indication: NSCLC) | A cancer peptide vaccine comprising four peptide antigens |
| 2) GRN-1301 | Basic research (Indication: NSCLC) | A cancer neoantigen peptide vaccine targeting non-small cell lung cancer with EGFR-T790M point mutation |
| 3) iPS-T cell therapy | Basic research (Indication: Lymphoma) | Induced pluripotent stem cell (iPSC)-derived, rejuvenated T cell therapy |
